Krishna Institute of Medical Sciences Ltd.
NSE: KIMSKrishna Institute of Medical Sciences Ltd.: A 30-second snapshot
Krishna Institute of Medical Sciences (KIMS) is a hospital-chain operator classified under the Pharma sector peer group, currently trading at ₹761.65 — 12.5% above its 50-DMA and 10.5% above its 200-DMA, with a 52-week drawdown of just 4.6%. The company reported FY26 revenue of ₹3,904 cr and PAT of ₹242 cr (profit margin 8.3%), against a trailing PE of 101.0 that sits at the top of the 6-stock peer set. Five-year revenue growth of 29.2% is offset by a cumulative earnings decline of 40.1% and a debt-to-equity of 123.7 with rising debt trend.
P/E
101.0
Forward P/E
39.7
ROE
—
Debt / Equity
123.72
Profit Margin
+8.3%
Div. Yield
—
5Y ROE > 15%
4/5
5Y FCF > 0
1/5
Quality
36/100
News
8 headlines · 4 positive · 1 negative
KIMS Hospitals FY26 Revenue ₹3,904cr; PAT ₹242cr - Whalesbook
Whalesbook
KIMS: Revenue rose but net profit and EPS declined due to one-time labor code expenses - TradingView
TradingView
Krishna Institute of Medical Sciences Targets 25-30% Revenue Growth Over Next Four Years - MSN
MSN
KIMS Hospitals Signs 60-Year Lease for 2 Acres in Amaravati to Build 500-Bed Multi-Speciality Hospital - scanx.trade
scanx.trade
500-bed multi-speciality hospital to come up in Amaravati, KIMS signs lease with APCRDA - The Hindu
The Hindu
Recent context
- ·FY26 results showed revenue of ₹3,904 cr and PAT of ₹242 cr; EPS declined due to one-time labour code expenses, which management described as non-recurring — the durability of that characterisation will be visible in Q1 FY27 margins.
- ·KIMS signed a 60-year lease with APCRDA for 2 acres in Amaravati to develop a 500-bed multi-speciality hospital, the most-covered news item in the corpus; management has guided 25–30% revenue growth over four years, implying further capex and debt.
- ·Analyst rating data is unavailable from the structured fundamental block; 15 analysts cover the stock per the data, but consensus direction cannot be characterised from the available fields.
Strengths
- +Revenue compounded at 29.2% over 5 years, reaching ₹3,904 cr in FY26, indicating sustained capacity additions translating into top-line expansion.
- +Price momentum over both 3-month (+11.4%) and 12-month (+15.6%) windows is positive; the stock trades above its 50-DMA and 200-DMA and is within 4.6% of its 52-week high.
- +ROE was above 15% in 4 of the available tracked years, suggesting periods of meaningful equity returns despite the current ROE data gap.
- +Active capacity expansion — including a 60-year lease for a 500-bed multi-speciality hospital in Amaravati — represents management execution on a visible growth roadmap, with reported targets of 25–30% revenue growth over the next four years.
Weaknesses
- −Earnings contracted 40.1% over 5 years even as revenue grew 29.2% — costs, interest charges, or non-recurring items are absorbing scale benefits; a one-time labour code expense was cited in the most recent earnings as a PAT headwind.
- −Debt-to-equity of 123.7 with a rising debt trend and free cash flow positive in only 1 of tracked years limits financial flexibility during a capital-intensive expansion cycle.
- −Quality score of 17 ranks 5th of 6 in the peer set; trailing PE of 101.0 is the highest among peers (vs MaxHealth 72.5, Apollo 64.5, Sun Pharma 41.3, Cipla 29.8, Dr. Reddy 26.5), placing the stock at the widest premium on a quality-to-valuation basis.
- −Profit margin of 8.29% with a consistency score of 48 reflects limited earnings quality relative to the capital deployed; ROE is currently unavailable, reducing comparability against peers.
Open questions
- ?If one-time labour code charges are genuinely non-recurring, what does the underlying PAT margin trajectory look like over the past four quarters — and does it show the directional improvement needed to justify the current PE?
- ?With D/E at 123.7 and FCF positive in only 1 tracked year, at what point does incremental debt for hospital expansion begin to materially constrain interest coverage ratios?
- ?The forward PE of 39.7 implies a substantial earnings re-acceleration embedded in current price — what specific operational levers (bed occupancy, ARPOB, mix shift) would need to materialise on what timeline for that earnings path to be plausible?
- ?Given that KIMS trades at the highest PE and lowest quality score in the peer set, what distinguishes its expansion pipeline or market positioning from MaxHealth or Apollo — and is that differentiation visible yet in operating metrics?
Peer comparison: Pharma
Ranks 5 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| KIMS | Krishna Institute of Medical Sciences Ltd.You're viewing | 101.0 | — | 17 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.5 | +11.8% | 17 |
Technical state
Current price
₹761.65
SMA 50
₹676.77
SMA 200
₹688.98
RSI (14)
65.8 (neutral)
From 52w high
-4.6%
1Y return
+15.6%
3M return
+11.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- high5-year earnings growth of -40.1% against revenue growth of 29.2% signals persistent margin erosion — costs and interest burden are expanding faster than revenue at scale.
- highDebt-to-equity of 123.7 is sharply elevated; free cash flow was positive in only 1 of the tracked years and debt trend is rising, creating meaningful solvency pressure during an active hospital-expansion phase.
- mediumTrailing PE of 101.0 is the highest among the 6 peers tracked (MaxHealth: 72.5, Apollo: 64.5, Sun Pharma: 41.3, Cipla: 29.8, Dr. Reddy: 26.5); quality score of 17 ranks 5th of 6 in the peer set.
- mediumProfit margin of 8.29%, consistency score of 48, and unavailable ROE data limit the ability to assess returns on equity at the current capital deployment level.
- lowNews corpus of 8 articles is lean; positive sentiment (4 of 8) is concentrated around the Amaravati 500-bed hospital expansion, a single forward-looking catalyst rather than broad operating performance improvement.
Cross-section contradictions
- Revenue expanded 29.2% over 5 years while earnings contracted 40.1% over the same period — an unusual divergence suggesting cost structures or interest charges are compounding faster than operating scale benefits.
- Price is 15.6% higher over 1 year, trades above both the 50-DMA (₹676.8) and 200-DMA (₹689.0), and sits only 4.6% below its 52-week high — yet the quality score of 17 ranks last or near-last in the peer group and FCF was positive in only 1 of tracked years.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days